[iudqnolq]

Behind the scenes, to the extent significant, the third party risk when it comes to drug quality is identical and low.

Pharma charges goodRx less because it's market segmentation - they're assuming many goodRx users would otherwise just suffer without and thus generate no profit.

Some people speculate goodRx subsidizes prices by selling data. I don't find their analysis convincing as they don't explain how goodRx has data meaningfully more valuable than the data pharma already buys from other sources like pharmacies.